comparemela.com

Kami Maddocks News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Novel Combination Active in Large B-Cell Lymphoma, Even After CAR-T

But where mosunetuzumab/polatuzumab vedotin would fit among available options remains a question

United statesYazeed sawalhaGreg laubKami maddocksDavid bondOhio state university wexner medical centerAmerican society of hematologyAmerican societyMedpage todayFavorable safety profileRefractory largeb cell lymphomaPrimary analysisSenior director

Pirtobrutinib Shows Potential in Heavily Pretreated Follicular Lymphoma

'Safety profile is one of the real advantages' of non-covalent BTK inhibitor, says panelist

United statesYazeed sawalhaDavid bondKami maddocksGreg laubAmerican society of hematologyOhio state university wexner medical centerAmerican societyMedpage todayHighly selectiveRefractory follicular lymphomaSenior director

Liso-Cel a Potential New CAR-T Option for High-Risk R/R Follicular Lymphoma

Study results show impressive efficacy, favorable safety profile in the second line

United statesGreg laubKami maddocksDavid bondYazeed sawalhaOhio state university wexner medical centerAmerican society of hematologyAmerican societyMedpage todaySenior director

Axi-Cel Shows Durable Responses, Prolongs Overall Survival in Older LBCL Patients

Our panel discusses findings from the ZUMA-12 study and the ZUMA-7 study

United statesGreg laubDavid bondKami maddocksYazeed sawalhaAmerican society of hematologyOhio state university wexner medical centerAmerican societyMedpage todaySenior director

Positive Results for Odronextamab in Relapsed/Refractory DLBCL

But experts aren't sure where it would fit in with currently approved bispecifics

United statesKami maddocksKamij maddocksYazeed sawalhaYazeedy sawalhaOhio state university wexner medical centerOhio state university james comprehensive cancer centerOhio state universityAmerican society of hematologyAmerican societyMedpage todayIm yazeed sawalhaOhio stateKim david

vimarsana © 2020. All Rights Reserved.